Quarterly report [Sections 13 or 15(d)]

Note 3 - Liquidity, Management's Plans and Going Concern

v3.26.3
Note 3 - Liquidity, Management's Plans and Going Concern
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Substantial Doubt about Going Concern [Text Block]

3.         Liquidity, Management’s Plans and Going Concern

 

As of September 30, 2026 and December 31, 2025, the Company has an accumulated deficit of $204.3 million and $172.8 million, respectively, and the Company has not generated positive cash flow from operations since its inception.

 

Additional funding will be required to continue the Company’s research and development and other operating activities. In the next 12 months we will likely seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data were not positive or economic and market conditions deteriorate.

 

Our most recent equity financings include our July 2025 private placement in which we issued and sold an aggregate of 8,606,425 common shares pursuant to a securities purchase agreement at a purchase price of $3.50 per share to accredited investors. As a result of the offering, we received net proceeds of $30.0 million, after deducting offering expenses. Additionally, we sold 1,724,472 common shares under our at-the-market offering for net proceeds of $13.3 million.

 

If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that may include, among other things, reducing use of outside professional service providers, reducing personnel or personnel compensation, significantly modifying or delaying the development of our DM199 product candidate, licensing to third parties the rights to commercialize our DM199 product candidate or ceasing operations.

 

Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability to obtain required governmental approvals of our product candidate and ultimately our ability to license or market and sell our DM199 product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are not successful or if we are unable to obtain required governmental approvals, we would not be able to continue as a going concern and would be forced to cease operations and liquidate our company.

 

There can be no assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional equity securities would likely result in dilution to our current shareholders.